479 related articles for article (PubMed ID: 25483508)
1. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
2. Recent developments in therapeutic cancer vaccines.
Morse MA; Chui S; Hobeika A; Lyerly HK; Clay T
Nat Clin Pract Oncol; 2005 Feb; 2(2):108-13. PubMed ID: 16264883
[TBL] [Abstract][Full Text] [Related]
3. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
4. MAGE-A3: an immunogenic target used in clinical practice.
Esfandiary A; Ghafouri-Fard S
Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
[TBL] [Abstract][Full Text] [Related]
5. Challenges for cancer vaccine development.
Tabi Z; Man S
Adv Drug Deliv Rev; 2006 Oct; 58(8):902-15. PubMed ID: 16979786
[TBL] [Abstract][Full Text] [Related]
6. New frontiers in cell-based immunotherapy of cancer.
D'Elios MM; Del Prete G; Amedei A
Expert Opin Ther Pat; 2009 May; 19(5):623-41. PubMed ID: 19441938
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy targeting the telomerase reverse transcriptase.
Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
[TBL] [Abstract][Full Text] [Related]
8. Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
Tuyaerts S; Aerts JL; Corthals J; Neyns B; Heirman C; Breckpot K; Thielemans K; Bonehill A
Cancer Immunol Immunother; 2007 Oct; 56(10):1513-37. PubMed ID: 17503040
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines: Where are we going?
Cebon J
Asia Pac J Clin Oncol; 2010 Mar; 6 Suppl 1():S9-15. PubMed ID: 20482531
[TBL] [Abstract][Full Text] [Related]
10. Overview of the cancer vaccine field: are we moving forward?
Kudrin A; Hanna MG
Hum Vaccin Immunother; 2012 Aug; 8(8):1135-40. PubMed ID: 22854670
[TBL] [Abstract][Full Text] [Related]
11. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
13. A New Generation of Vaccines in the Age of Immunotherapy.
Addeo A; Friedlaender A; Giovannetti E; Russo A; de Miguel-Perez D; Arrieta O; Cardona AF; Rolfo C
Curr Oncol Rep; 2021 Nov; 23(12):137. PubMed ID: 34735649
[TBL] [Abstract][Full Text] [Related]
14. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
15. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells in cancer immunotherapy.
Vulink A; Radford KJ; Melief C; Hart DN
Adv Cancer Res; 2008; 99():363-407. PubMed ID: 18037410
[TBL] [Abstract][Full Text] [Related]
17. Part I: Vaccines for solid tumours.
Mocellin S; Mandruzzato S; Bronte V; Lise M; Nitti D
Lancet Oncol; 2004 Nov; 5(11):681-9. PubMed ID: 15522656
[TBL] [Abstract][Full Text] [Related]
18. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
Spisek R
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
[No Abstract] [Full Text] [Related]
19. Cancer vaccines: between the idea and the reality.
Finn OJ
Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
[TBL] [Abstract][Full Text] [Related]
20. Update on vaccines for solid tumors.
Gajewski TF
Clin Adv Hematol Oncol; 2004 Mar; 2(3):158-9. PubMed ID: 16166944
[No Abstract] [Full Text] [Related]
[Next] [New Search]
